NASDAQ:IDXX - IDEXX Laboratories Stock Price, Forecast & News

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings results on Thursday, October, 31st. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.14 by $0.10. The business earned $605.30 million during the quarter, compared to analyst estimates of $597.09 million. IDEXX Laboratories had a net margin of 17.99% and a return on equity of 405.71%. The firm's revenue was up 11.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.05 earnings per share. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Friday, January 31st 2020. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories will be holding an earnings conference call on Friday, January 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

IDEXX Laboratories issued an update on its FY20 earnings guidance on Thursday, October, 31st. The company provided earnings per share (EPS) guidance of $5.30-5.46 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.56. The company issued revenue guidance of $2.61-2.65 billion, compared to the consensus revenue estimate of $2.63 billion.

6 analysts have issued 1 year price targets for IDEXX Laboratories' shares. Their forecasts range from $277.00 to $310.00. On average, they expect IDEXX Laboratories' stock price to reach $293.33 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

News coverage about IDXX stock has been trending positive this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. IDEXX Laboratories earned a news impact score of 2.9 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for IDEXX Laboratories.

IDEXX Laboratories saw a decline in short interest during the month of December. As of December 13th, there was short interest totalling 1,310,000 shares, a decline of 10.3% from the November 28th total of 1,460,000 shares. Based on an average trading volume of 463,700 shares, the short-interest ratio is currently 2.8 days. Approximately 1.6% of the company's shares are short sold. View IDEXX Laboratories' Current Options Chain.

Some companies that are related to IDEXX Laboratories include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Paypal (PYPL), Netflix (NFLX), Adobe (ADBE), Alibaba Group (BABA), Home Depot (HD), Mastercard (MA), Intuitive Surgical (ISRG), Micron Technology (MU) and ServiceNow (NOW).

IDEXX Laboratories' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Welch & Forbes LLC (0.21%), Chicago Capital LLC (0.11%), Nisa Investment Advisors LLC (0.07%), Woodstock Corp (0.05%), Spence Asset Management (0.05%) and State of Alaska Department of Revenue (0.04%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Meag Munich Ergo Kapitalanlagegesellschaft MBH, DNB Asset Management AS, First Hawaiian Bank, Cribstone Capital Management LLC, State of Alaska Department of Revenue, Calamos Wealth Management LLC and Tuttle Tactical Management. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Johanson Financial Advisors Inc., Pensionfund DSM Netherlands, Pensionfund Sabic, Cerebellum GP LLC, Baxter Bros Inc., Red Spruce Capital LLC and Washburn Capital Management Inc.. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $285.80.

IDEXX Laboratories has a market capitalization of $24.52 billion and generates $2.21 billion in revenue each year. The company earns $377.03 million in net income (profit) each year or $4.26 on an earnings per share basis. IDEXX Laboratories employs 8,377 workers across the globe.View Additional Information About IDEXX Laboratories.

The official website for IDEXX Laboratories is http://www.idexx.com/.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]